NIOX Group plc is a UK-based medical device company focused exclusively on point-of-care asthma diagnosis and management. The company's flagship product is the NIOX VERO system, a non-invasive diagnostic device that measures fractional exhaled nitric oxide (FeNO) to help healthcare professionals diagnose asthma, determine responsiveness to inhaled corticosteroids, and monitor treatment compliance. The system comprises a portable, reusable device along with consumable sensors and disposable mouthpieces. In addition to clinical settings, NIOX VERO is widely utilized by clinical research organizations for respiratory studies. Headquartered in Oxford, the company distributes its products in over 50 countries through direct sales operations in the UK, US, Germany, Sweden, and China, as well as an extensive international distributor network. The company was formerly known as Circassia Group plc before rebranding in 2022, following a strategic pivot away from its legacy pharmaceutical and COPD businesses to focus entirely on its respiratory diagnostics platform.
